178 related articles for article (PubMed ID: 35847495)
1. Remodeling "cold" tumor immune microenvironment
He Y; Fang Y; Zhang M; Zhao Y; Tu B; Shi M; Muhitdinov B; Asrorov A; Xu Q; Huang Y
Acta Pharm Sin B; 2022 Apr; 12(4):2057-2073. PubMed ID: 35847495
[TBL] [Abstract][Full Text] [Related]
2. Metabolic modulation via mTOR pathway and anti-angiogenesis remodels tumor microenvironment using PD-L1-targeting codelivery.
Chen B; Gao A; Tu B; Wang Y; Yu X; Wang Y; Xiu Y; Wang B; Wan Y; Huang Y
Biomaterials; 2020 Oct; 255():120187. PubMed ID: 32590192
[TBL] [Abstract][Full Text] [Related]
3. Reprogramming Tumor Immune Microenvironment (TIME) and Metabolism via Biomimetic Targeting Codelivery of Shikonin/JQ1.
Wang H; Tang Y; Fang Y; Zhang M; Wang H; He Z; Wang B; Xu Q; Huang Y
Nano Lett; 2019 May; 19(5):2935-2944. PubMed ID: 30950276
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic-based combination therapy and liposomal codelivery overcomes osimertinib-resistant NSCLC via repolarizing tumor-associated macrophages.
Lin TT; Xiong W; Chen GH; He Y; Long L; Gao XF; Zhou JL; Lv WW; Huang YZ
Acta Pharmacol Sin; 2024 Apr; 45(4):867-878. PubMed ID: 38114644
[TBL] [Abstract][Full Text] [Related]
5. Deformable liposomal codelivery of vorinostat and simvastatin promotes antitumor responses through remodeling tumor microenvironment.
Tu B; He Y; Chen B; Wang Y; Gao Y; Shi M; Liu T; Asrorov AM; Huang Y
Biomater Sci; 2020 Dec; 8(24):7166-7176. PubMed ID: 33169732
[TBL] [Abstract][Full Text] [Related]
6. Nano-Regulator Inhibits Tumor Immune Escape via the "Two-Way Regulation" Epigenetic Therapy Strategy.
Liang S; Liu M; Mu W; Gao T; Gao S; Fu S; Yuan S; Liu J; Liu Y; Jiang D; Zhang N
Adv Sci (Weinh); 2024 Mar; 11(9):e2305275. PubMed ID: 38110834
[TBL] [Abstract][Full Text] [Related]
7. Dual-targeting biomimetic delivery for anti-glioma activity
Zhao P; Wang Y; Kang X; Wu A; Yin W; Tang Y; Wang J; Zhang M; Duan Y; Huang Y
Chem Sci; 2018 Mar; 9(10):2674-2689. PubMed ID: 29732051
[TBL] [Abstract][Full Text] [Related]
8. Lactoferrin-Modified Gambogic Acid Liposomes for Colorectal Cancer Treatment.
Wang R; Qu J; Tang X; Zhang J; Ou A; Li Q; Chen G; Zheng C; Muhitdinov B; Huang Y
Mol Pharm; 2023 Aug; 20(8):3925-3936. PubMed ID: 37505210
[TBL] [Abstract][Full Text] [Related]
9. On-demand integrated nano-engager converting cold tumors to hot
Liu X; Liang S; Sang X; Chang L; Fu S; Yang H; Yang H; Liu Y; Zhang N
Acta Pharm Sin B; 2023 Apr; 13(4):1740-1754. PubMed ID: 37139406
[TBL] [Abstract][Full Text] [Related]
10. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
11. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
[TBL] [Abstract][Full Text] [Related]
12. BET inhibitor JQ1 enhances anti-tumor immunity and synergizes with PD-1 blockade in CRC.
Wang H; Liu G; Jin X; Song S; Chen S; Zhou P; Li H; Liang J; Li B; Zhang C; He Y
J Cancer; 2022; 13(7):2126-2137. PubMed ID: 35517410
[TBL] [Abstract][Full Text] [Related]
13. Sialic acid conjugate-modified liposomal platform modulates immunosuppressive tumor microenvironment in multiple ways for improved immune checkpoint blockade therapy.
Li C; Qiu Q; Gao X; Yan X; Fan C; Luo X; Liu X; Wang S; Lai X; Song Y; Deng Y
J Control Release; 2021 Sep; 337():393-406. PubMed ID: 34171446
[TBL] [Abstract][Full Text] [Related]
14. Magnetism-mediated targeting hyperthermia-immunotherapy in "cold" tumor with CSF1R inhibitor.
Fang Y; He Y; Wu C; Zhang M; Gu Z; Zhang J; Liu E; Xu Q; Asrorov AM; Huang Y
Theranostics; 2021; 11(14):6860-6872. PubMed ID: 34093858
[No Abstract] [Full Text] [Related]
15. The Bromodomain Inhibitor JQ1 and the Histone Deacetylase Inhibitor Panobinostat Synergistically Reduce N-Myc Expression and Induce Anticancer Effects.
Shahbazi J; Liu PY; Atmadibrata B; Bradner JE; Marshall GM; Lock RB; Liu T
Clin Cancer Res; 2016 May; 22(10):2534-44. PubMed ID: 26733615
[TBL] [Abstract][Full Text] [Related]
16. Remodeling tumor immune microenvironment via targeted blockade of PI3K-γ and CSF-1/CSF-1R pathways in tumor associated macrophages for pancreatic cancer therapy.
Li M; Li M; Yang Y; Liu Y; Xie H; Yu Q; Tian L; Tang X; Ren K; Li J; Zhang Z; He Q
J Control Release; 2020 May; 321():23-35. PubMed ID: 32035193
[TBL] [Abstract][Full Text] [Related]
17. Engineering Endogenous Tumor-Associated Macrophage-Targeted Biomimetic Nano-RBC to Reprogram Tumor Immunosuppressive Microenvironment for Enhanced Chemo-Immunotherapy.
Wang Y; Yu J; Luo Z; Shi Q; Liu G; Wu F; Wang Z; Huang Y; Zhou D
Adv Mater; 2021 Oct; 33(39):e2103497. PubMed ID: 34387375
[TBL] [Abstract][Full Text] [Related]
18. Engineered a dual-targeting biomimetic nanomedicine for pancreatic cancer chemoimmunotherapy.
Wang M; Hu Q; Huang J; Zhao X; Shao S; Zhang F; Yao Z; Ping Y; Liang T
J Nanobiotechnology; 2022 Feb; 20(1):85. PubMed ID: 35177078
[TBL] [Abstract][Full Text] [Related]
19. Breast Cancer Chemo-immunotherapy through Liposomal Delivery of an Immunogenic Cell Death Stimulus Plus Interference in the IDO-1 Pathway.
Lu J; Liu X; Liao YP; Wang X; Ahmed A; Jiang W; Ji Y; Meng H; Nel AE
ACS Nano; 2018 Nov; 12(11):11041-11061. PubMed ID: 30481959
[TBL] [Abstract][Full Text] [Related]
20. Molecular-Targeted Immunotherapeutic Strategy for Melanoma via Dual-Targeting Nanoparticles Delivering Small Interfering RNA to Tumor-Associated Macrophages.
Qian Y; Qiao S; Dai Y; Xu G; Dai B; Lu L; Yu X; Luo Q; Zhang Z
ACS Nano; 2017 Sep; 11(9):9536-9549. PubMed ID: 28858473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
